secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0000950170-24-129750
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout
--------------------------------------------------------------------------------

- Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.
- Earnout tied to Extract Labs revenue targets: $3.5M-$4.6M per 12-month period for two years.
- Acquisition expected to close in Q1 2025, subject to customary conditions.
- CV Sciences plans to in-source +PlusCBD production, citing cost savings and supply chain control.
- Extract Labs described as stand-alone profitable, GMP-certified, and FDA-registered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/0000950170-24-129750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/cvsi-20241115.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer